Becton, Dickinson and Company provides solutions which are focused on improving medication management and patient safety, supporting infection prevention practices, equipping surgical and interventional procedures, improving drug delivery, aiding anesthesiology and respiratory care, advancing cellular research and applications, enhancing the diagnosis of infectious diseases and cancers, and supporting the management of diabetes. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
BDX Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Becton Dickinson & Co with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Becton Dickinson & Co ranked in the 37th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Becton Dickinson & Co, consider:
As a business, BDX is generating more cash flow than 87.45% of positive cash flow stocks in the Healthcare.
Becton Dickinson & Co's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 22.65% of tickers in our DCF set.
Becton Dickinson & Co's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than just 0% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Becton Dickinson & Co? See DGX, EBS, ICLR, RSCF, and STE.
Becton, Dickinson & Company (BDX) announces its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor Plus System has been CE marked to the IVD Directive (98/79/EC). The new test delivers results in 15 minutes on an easy-to-use, portable instrument. This new assay is expected to be commercial...
A new coronavirus test that delivers results in just 15 minutes will be available in Europe next month, New Jersey-based medical-device maker Becton Dickinson announced Wednesday. The company expects to start selling its rapid COVID-19 test in the European Union countries by the end of October now that it’s met the requirements to launch the…
Summary List Placement A Becton Dickinson lab-free COVID-19 test that returns results in 15 minutes has been cleared for use in Europe. The US medical device maker said on Wednesday that its testing kit for coronavirus, which has been available in the US since July, met the requirements to be sold in Europe. It will be available in countries that recognize the CE mark, which shows that a manufacturer has ensured a product meets European Union safety requirements. Becton Dickinson said it expects its test to be commercially available in European markets by the end of October. It will most likely be used by emergency departments, pediatricians, and general practitioners, it said. The portable BD Veritor Plus System can quickly identify antigens on the surface of the coronavirus without re...
The Franklin Lakes, New Jersey-based company said the settlement resolved litigation involving the former CR Bard Inc, which it acquired in 2017. In related court papers, New York Attorney General Letitia James said CR Bard misrepresented or failed to disclose risks associated with the devices, including chronic pain, vaginal scarring, vaginal shortening, infection and inflammation.
Medical-testing firm Becton Dickinson says it’s investigating false-positive coronavirus test results reported at nursing homes around the US. The New Jersey-based company, also known as BD, said a “small number” of nursing homes are reporting multiple false-positive COVID-19 tests from its Veritor Plus machine, which can deliver results in 15 minutes. Roughly a dozen sites…